Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups

Ellen Rafferty (), Mike Paulden, Sarah A. Buchan, Joan L. Robinson, Julie A. Bettinger, Manoj Kumar, Lawrence W. Svenson and Shannon E. MacDonald
Additional contact information
Ellen Rafferty: University of Alberta
Mike Paulden: University of Alberta
Sarah A. Buchan: Public Health Ontario
Joan L. Robinson: University of Alberta
Julie A. Bettinger: BC Children’s Hospital and University of British Columbia
Manoj Kumar: University of Alberta
Lawrence W. Svenson: University of Alberta
Shannon E. MacDonald: University of Alberta

PharmacoEconomics, 2022, vol. 40, issue 6, No 6, 633-645

Abstract: Abstract Background Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI), with high morbidity and mortality worldwide. RSV costing and burden estimates can highlight the potential benefits of future vaccination programs and are essential for economic evaluations. Objective We aimed to determine RSV healthcare costs across age groups and the overall disease burden of medically attended RSV in Canada. Methods We conducted a retrospective case–control study to estimate the attributable healthcare costs per RSV case in Alberta. We used two case definitions to capture diversity in case severity: laboratory-confirmed RSV and ARI attributable to RSV. Matching occurred on five criteria: (1) age, (2) urban/rural status, (3) sex, (4) prematurity and (5) Charlson Comorbidity Index score. We calculated the age-specific burden of medically attended RSV in Canada from 2010 to 2019 by multiplying the weekly age-specific incidence of medically attended ARI with the RSV positivity rate. Results Costs per laboratory-confirmed RSV case were (in Canadian dollars [CAD], year 2020 values) $CAD12,713 and 40,028 in the first 30 and 365 days following diagnosis, respectively, whereas a case of ARI potentially attributable to RSV cost $CAD316 and 915, in 30 and 365 days, respectively. Older (aged ≥ 65 years) and younger (aged

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-022-01142-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:40:y:2022:i:6:d:10.1007_s40273-022-01142-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-022-01142-w

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().